Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVINCE colchicine for secondary prevention after non-cardioembolic stroke or high-risk TIA
NL-OMON49701Phase 3Recruiting
- Sponsor
- University College Dublin
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colchicine in ischemic stroke, transient ischaemic attack (TIA) and cerebrovascular disease (2 arms), sponsored by University College Dublin. Primary endpoint: Primary composite efficacy outcome. Started Mar 2021; status: recruiting.
02
Drugs
colchicine
03
Conditions
ischemic stroketransient ischaemic attack (TIA)cerebrovascular disease
Beyond the preview
Go deeper on NL-OMON49701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49701.